Communiqués Iterum Therapeutics plc

Actions

ITRM

IE000TTOOBX0

Marché Fermé - Nasdaq Autres places de cotation 22:30:01 01/07/2024			Varia. 5j.	Varia. 1 janv.
1,095 ^USD	-4,37 %		-6,41 %	-44,42 %

21/06	Mise à jour sectorielle : Les actions du secteur de la santé gagnent en fin d'après-midi	MT
21/06	Mise à jour sectorielle : Soins de santé	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Iterum Therapeutics Announces FDA Advisory Committee Meeting to discuss NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections	21/06	AQ
Iterum Therapeutics to Present Data at ASM Microbe 2024	05/06	AQ
Iterum Therapeutics Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections	31/05	AQ
Iterum Therapeutics Reports First Quarter 2024 Financial Results	13/05	AQ
Iterum Therapeutics to Report First Quarter 2024 Financial Results on May 13, 2024	06/05	AQ
Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem	29/04	AQ
Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results	28/03	AQ
Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024	21/03	AQ
Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chat	15/03	AQ
Iterum Therapeutics Provides Business Update	06/03	AQ
Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections	30/01	PR
Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule	04/12	AQ
Iterum Therapeutics Reports Third Quarter 2023 Financial Results	14/11	AQ
Iterum Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on November 14, 2023	07/11	AQ
Iterum Therapeutics Announces Completion of Enrollment in its REASSURE Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections	24/10/23	AQ
Iterum Therapeutics to Present Data at IDWeek 2023	12/10/23	AQ
Iterum Therapeutics : Failure to Satisfy Listing Rule - Form 8-K	02/10/23	PU
Iterum Therapeutics Reports Second Quarter 2023 Financial Results	14/08/23	AQ
Iterum Therapeutics Reports Second Quarter 2023 Financial Results	11/08/23	AQ
Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023	07/08/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Iterum Therapeutics plc

Actions

ITRM

IE000TTOOBX0

Communiqués

Filtres